Sign in

CIK 0001880438

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

AN2 Therapeutics, Inc.

Sign in to watch
Ticker
ANTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
820606654
Phone
+1 650-331-9090
Business address
1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
  1. 4 Grant or award Eizen Joshua M acquired 58,500 shares (grant or award)
  2. 4 Grant or award Chief Executive Officer acquired 145,250 shares (grant or award)
  3. 4 Grant or award Chief Strategy Officer acquired 28,000 shares (grant or award)
  4. 4 Open-market sale Chief Financial Officer sold 2,957 shares at $1.34 ($3,965)
  5. 4 Open-market sale Chief Development Officer sold 2,957 shares at $1.34 ($3,965)
  6. 4 Open-market sale Chief Strategy Officer sold 2,029 shares at $1.34 ($2,721)
  7. 4 Open-market sale Eizen Joshua M sold 9,663 shares at $1.34 ($12,958)
  8. 4 Grant or award Director acquired 3,166 shares (grant or award)
  9. 4 Grant or award Director acquired 8,972 shares (grant or award)
  10. 4 Grant or award Director acquired 8,972 shares (grant or award)
  11. 4 Grant or award Director acquired 9,816 shares (grant or award)
  12. 4 Grant or award Director acquired 9,077 shares (grant or award)
  13. 4 Open-market buy Director bought 60,000 shares at an average $1.45 ($86,708)
  14. 4 Open-market buy Director bought 75,000 shares at an average $1.41 ($105,685)
  15. 4 Open-market buy Director bought 2,000 shares at $1.40 ($2,800)
  16. 4 Open-market buy Director bought 200,000 shares at an average $1.07 ($213,128)
  17. 4 Open-market buy Director bought 25,000 shares at an average $1.00 ($25,046)
  18. 4 Open-market buy Chief Executive Officer bought 50,000 shares at $1.00 ($49,970)
  19. 4 Grant or award Chief Strategy Officer acquired 10,125 shares (grant or award)
  20. 4 Grant or award Eizen Joshua M acquired 31,500 shares (grant or award)

Page 5 of 11 · 216 filings